Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RCKT Rocket Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: RCKT
Price (delayed)
$6.5
Market cap
$700.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.63
Enterprise value
$673.96M
Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it
Highlights
Rocket Pharmaceuticals's EPS has increased by 8% YoY and by 3.7% from the previous quarter
The debt has declined by 2.3% year-on-year
The equity has declined by 11% since the previous quarter and by 7% year-on-year
The quick ratio has declined by 10% year-on-year
Key stats
What are the main financial stats of RCKT
Market
Valuations
Earnings
Shares outstanding
107.74M
Market cap
$700.3M
Enterprise value
$673.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$270.22M
Net income
-$258.03M
EBIT
-$256.14M
EBITDA
-$246.03M
Free cash flow
-$212.85M
Per share
Balance sheet
Liquidity
EPS
-$2.63
EPS diluted
-$2.63
Free cash flow per share
-$1.93
Book value per share
$3.87
Revenue per share
$0
TBVPS
$3.69
Total assets
$471.07M
Total liabilities
$58.93M
Debt
$25.35M
Equity
$412.14M
Working capital
$289.18M
Debt to equity
0.06
Current ratio
9.19
Quick ratio
9.06
Net debt/EBITDA
0.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-56.1%
Return on equity
-64.9%
Return on invested capital
-85%
Return on capital employed
-58.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCKT stock price
How has the Rocket Pharmaceuticals stock price performed over time
Intraday
-3.35%
1 week
-7.01%
1 month
5.69%
1 year
-72.22%
YTD
-48.29%
QTD
-2.55%
Financial performance
How have Rocket Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$270.22M
Net income
-$258.03M
Gross margin
N/A
Net margin
N/A
RCKT's net income is down by 3.5% YoY
The operating income has contracted by 2% YoY
Price vs fundamentals
How does RCKT's price correlate with its fundamentals
Growth
What is Rocket Pharmaceuticals's growth rate over time
Valuation
What is Rocket Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rocket Pharmaceuticals's EPS has increased by 8% YoY and by 3.7% from the previous quarter
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 4.0 and 53% less than its last 4 quarters average of 3.6
The equity has declined by 11% since the previous quarter and by 7% year-on-year
Efficiency
How efficient is Rocket Pharmaceuticals business performance
The ROIC has contracted by 25% YoY and by 3.5% from the previous quarter
RCKT's ROE is down by 22% YoY
The return on assets has declined by 20% year-on-year
Dividends
What is RCKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCKT.
Financial health
How did Rocket Pharmaceuticals financials performed over time
Rocket Pharmaceuticals's current ratio has decreased by 12% YoY
Rocket Pharmaceuticals's total assets has decreased by 11% from the previous quarter and by 6% YoY
The debt is 94% smaller than the equity
The equity has declined by 11% since the previous quarter and by 7% year-on-year
The debt has declined by 2.3% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.